title: Cytomegalovirus infection in children who underwent hematopoietic stem cell transplantation at a single center: a retrospective study of the risk factors.
abstract: CMV infection is one of the major causes of morbidity and mortality after HSCT. The aim of this single center retrospective study was to analyze risk factors for CMV infection in pediatric patients who underwent HSCT. We retrospectively reviewed the medical records of 117 pediatric patients who underwent allogeneic HSCT at Asan Medical Center between December 2000 and January 2007. After HSCT, CMV antigenemia was detected by identifying CMV pp65 early antigen in white blood cells. The incidence of CMV antigenemia was 24% (28/117) at a median of 38 days (range: 19-123 days) after HSCT. In multivariate analysis, CMV antigenemia occurred significantly more often in CMV seropositive recipients, patients who received grafts from alternative donors, T-cell depleted grafts, patients on ATG-containing conditioning regimens, or patients who received steroid for acute GVHD (p < 0.05). CMV antigenemia tend to develop earlier in patients who received ATG-containing conditioning regimens (p = 0.09). A second episode of CMV antigenemia was observed in three out of 28 patients (11%). The incidence of CMV disease was 5.9% (7/117) at a median of 97 days (range: 34-120 days). Manifestation of CMV disease included retinitis in two, pneumonitis in two, hepatitis in one, hepatitis with colitis in one, and gastritis in one. Six of the 12 patients (50%) with HG antigenemia (CMV pp65 antigen positivity > or =40 cells) developed clinical CMV disease, a rate that was significantly higher than seen in patients with LG antigenemia (6.25%; p < 0.01). We recommend that patients with these risk factors should carefully undergo regular evaluations for CMV infection. We also suggest that earlier and more aggressive preemptive treatment and serial follow-up of CMV disease is necessary in patients with HG-antigenemia.
authors.affiliation: Department of Pediatrics, Kyung-Hee University Medical Center, Seoul, Korea.
authors.forename: Hoi Soo
authors.initials: HS
authors.lastname: Yoon
authors.forename: Jae Hee
authors.initials: JH
authors.lastname: Lee
authors.forename: Eun Soek
authors.initials: ES
authors.lastname: Choi
authors.forename: Jong Jin
authors.initials: JJ
authors.lastname: Seo
authors.forename: Hyung Nam
authors.initials: HN
authors.lastname: Moon
authors.forename: Mi-Na
authors.initials: MN
authors.lastname: Kim
authors.forename: Ho Joon
authors.initials: HJ
authors.lastname: Im
mesh_terms: D000293:Adolescent; D000998:Antiviral Agents / Q000494:pharmacology; D002648:Child; D002675:Child, Preschool; D003586:Cytomegalovirus Infections / Q000150:complications / Q000209:etiology*; D005260:Female; D006086:Graft vs Host Disease / Q000097:blood; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D007223:Infant; D007962:Leukocytes / Q000378:metabolism; D008297:Male; D015999:Multivariate Analysis; D010750:Phosphoproteins / Q000096:biosynthesis; D012189:Retrospective Studies; D012307:Risk Factors; D014763:Viral Matrix Proteins / Q000096:biosynthesis
chemical_list: D000998:Antiviral Agents; D010750:Phosphoproteins; D014763:Viral Matrix Proteins; C065418:cytomegalovirus matrix protein 65kDa